Chief, Cellular Immunology Section, NIH Vaccine Research Center
Appears in 1 story
Leading MAD21-101 antibody research and monoclonal antibody trials
NIH researchers discovered a new class of antibodies that attack malaria parasites at a never-before-targeted site. The antibody MAD21-101 protected four out of five mice from infection, working differently than existing vaccines by binding to a cryptic protein fragment exposed only after the parasite undergoes pyroglutamylation, a specific chemical transformation. This opens a fresh avenue in the decades-long hunt for a highly effective malaria vaccine.
Updated May 19
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
